
PZA Innovation: Developing reliable tuberculosis drugs through reverse engineering and in-vivo sterilization.
PZA Innovation was founded with the core mission of developing reliable tuberculosis drugs through innovative methods such as reverse engineering and in-vivo sterilization. The company focuses on addressing the global challenge of pyrazinamide (PZA)-resistant tuberculosis by creating accurate and reliable PZA susceptibility tests. Their work aims to improve clinical outcomes for the millions of new PZA-resistant TB cases annually by ensuring that PZA can effectively shorten the treatment duration from 9-12 months to 6 months.
Notable affiliated individuals and investors include experts in microbiology and pharmacology, though specific names are not provided. Key achievements of PZA Innovation include pioneering a method to determine the conditions under which pyrazinamide is active in vitro, thereby enhancing its efficacy in vivo. The overall impact of their work is significant, as it addresses a critical gap in tuberculosis treatment and has the potential to improve patient outcomes globally by ensuring more effective use of existing drugs.
PZA Innovation's most recent funding round was for $250.5k (USD) in December 2021.
As of Dec 28, 2021, PZA Innovation has disclosed funding of $250.5k (USD).
Global BioDiagnostics

Poseidon Innovation

Fzata
fzata.com

Inventprise
inventprise.com

Bridge Medicines

Zero Point Five Therapeutics
PNA Innovations

Praxis Bioresearch

Curza
curza.com

Antibiotic Adjuvant
a-adjuvant.com

TAXIS Pharmaceuticals
taxispharma.com

Microbion
microbioncorp.com
Praesidia Biologics
Ziran Biopharmaceutical

ArrePath
arrepath.com

Ezra Innovations
ezrapharma.com

PhagePro
phageproinc.com

Pinpoint Pharma
pinpointpharma.co

Zymeron
zymeron.com
Zabecor Pharmaceuticals